[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100241475":3},{"organization":4,"outcomesModule":7,"designInfo":48,"detailedDescription":20,"studyPopulation":51,"armGroups":20,"interventions":52,"overallOfficials":58,"centralContacts":62,"locations":68,"responsibleParty":85,"collaborators":20,"id":87,"slug":20,"hasResults":88,"nctId":89,"briefTitle":90,"officialTitle":90,"acronym":20,"eligibilityCriteria":91,"healthyVolunteers":88,"sex":92,"minAge":93,"maxAge":20,"enrollmentInfo":94,"targetDuration":97,"studyType":98,"phases":20,"briefSummary":99,"conditions":100,"keywords":102,"overallStatus":70,"whyStopped":20,"lastUpdateSubmitDate":104,"lastUpdatePostDateStruct":105,"startDateStruct":108,"completionDateStruct":110,"leadSponsor":112,"locationsCount":113},{"fullName":5,"class":6},"University Medical Center Groningen","OTHER",{"primaryOutcomes":8,"secondaryOutcomes":17,"otherOutcomes":34},[9,13],{"measure":10,"description":11,"timeFrame":12},"Acute toxicity","esophagitis (Common Terminology Criteria for Adverse Events, version 4.0)","Highest during and within 2 weeks after last day of radiation therapy",{"measure":14,"description":15,"timeFrame":16},"Late toxicity","esophagitis (Common Terminology Criteria for Adverse Events, version 4.0); pneumonitis (Common Terminology Criteria for Adverse Events, version 4.0)","Highest within one year after last day of radiation therapy",[18,22,24,26,28,30,32,33],{"measure":19,"description":20,"timeFrame":21},"Overall survival",null,"at 1 year after first day of radiation therapy",{"measure":19,"description":20,"timeFrame":23},"at 2 years after first day of radiation therapy",{"measure":19,"description":20,"timeFrame":25},"at 3 years after first day of radiation therapy",{"measure":19,"description":20,"timeFrame":27},"at 4 years after first day of radiation therapy",{"measure":19,"description":20,"timeFrame":29},"at 5 years after first day of radiation therapy",{"measure":31,"description":20,"timeFrame":21},"Loco-regional tumor control",{"measure":31,"description":20,"timeFrame":23},{"measure":31,"description":20,"timeFrame":25},[35,38,40,42,44,45,46,47],{"measure":36,"description":20,"timeFrame":37},"Patient-rated symptoms and Quality-of-Life","Within 1 week before or after last day of radiation therapy",{"measure":36,"description":20,"timeFrame":39},"at 3 months after first day of radiation therapy",{"measure":36,"description":20,"timeFrame":41},"at 6 months after first day of radiation therapy",{"measure":36,"description":20,"timeFrame":43},"at one year after first day of radiation therapy",{"measure":36,"description":20,"timeFrame":23},{"measure":36,"description":20,"timeFrame":25},{"measure":36,"description":20,"timeFrame":27},{"measure":36,"description":20,"timeFrame":29},{"allocation":20,"interventionModel":20,"interventionModelDescription":20,"primaryPurpose":20,"observationalModel":49,"timePerspective":50,"maskingInfo":20},"COHORT","PROSPECTIVE","Patients with Non-Small Cell Lung Cancer (NSCLC) or Small Cell Lung Cancer - Limited Disease (SCLC-LD) or thymoma or lungmetastases (treated with stereotactic radiotherapy), receiving radiotherapy dose \\> 40 Gy.",[53],{"type":54,"name":55,"description":20,"armGroupLabels":20,"otherNames":56},"RADIATION","Radiotherapy",[57],"Chemoradiation",[59],{"name":60,"affiliation":5,"role":61},"Robin Wijsman, MD","PRINCIPAL_INVESTIGATOR",[63],{"name":64,"role":65,"phone":66,"phoneExt":20,"email":67},"Robin Wijsman, MD PhD","CONTACT","+31503615532","r.wijsman@umcg.nl",[69],{"facility":5,"status":70,"city":71,"state":72,"zip":73,"country":74,"countryCode":75,"cosmosGeoPoint":76,"geoPoint":81,"contacts":82},"RECRUITING","Groningen","Provincie Groningen","9700RB","Netherlands","NL",{"type":77,"coordinates":78},"Point",[79,80],6.56667,53.21917,{"lat":80,"lon":79},[83,84],{"name":60,"role":65,"phone":66,"phoneExt":20,"email":67},{"name":60,"role":61,"phone":20,"phoneExt":20,"email":20},{"type":86,"investigatorFullName":20,"investigatorTitle":20,"investigatorAffiliation":20,"oldNameTitle":20,"oldOrganization":20},"SPONSOR","100241475",false,"NCT02421718","Standard Follow-up Program (SFP) for Lung Cancer Patients Treated With Radiotherapy or Chemoradiation","Inclusion Criteria:\n\n* Patients with NSCLC or SCLC-LD or thymoma or lung metastases (treated with stereotactic radiotherapy)\n* Patients receiving radiotherapy dose \\> 40 Gy\n\nExclusion Criteria:\n\n* Failure to comply with any of the inclusion criteria","ALL","18 Years",{"count":95,"type":96},10000,"ESTIMATED","5 Years","OBSERVATIONAL","Motive:\n\nIn order to improve the treatment technique, a comprehensive follow-up program is needed to obtain all relevant patient, treatment and toxicity data from lung cancer patients.\n\nGoal:\n\nTo set-up and maintain a database containing treatment results in terms of tumor control, side effects, complications and patient-reported quality of life.\n\nA standard database of patients receiving photon treatment will be created. These data are then linked to dose-volume data of radiotherapy, with the aim to build prediction models for both tumor control and toxicity after radio (chemo) therapy that can later be used for selecting patients for proton treatment.",[101],"Lung Cancer",[10,14,103],"Prediction models","2026-04-28",{"date":106,"type":107},"2026-04-29","ACTUAL",{"date":109,"type":107},"2013-03",{"date":111,"type":96},"2031-12",{"name":5,"class":6},1]